Lamictal XR Shortage: What Providers and Prescribers Need to Know in 2026

Lamotrigine is one of the most commonly prescribed mood stabilizers and anticonvulsants in the United States, with over 10 million prescriptions written in 2023. While it does not appear on the FDA's official drug shortage list in 2026, neurologists, epileptologists, psychiatrists, and primary care physicians are increasingly encountering patients who cannot fill their Lamictal XR (lamotrigine extended-release) prescriptions — particularly for specific strengths or at specific pharmacy chains.

This clinical briefing covers the current supply picture, the structural factors driving pharmacy-level stock-outs, prescribing strategies to protect your patients, and resources to share with your care team.

Current Supply Situation for Lamictal XR

As of 2026, lamotrigine immediate-release (IR) is generally well-stocked at most retail pharmacies. The extended-release formulation (Lamictal XR / lamotrigine ER) presents a different picture:

• Lower prescription volume than IR means pharmacies carry smaller baseline stock of the XR formulation
• Fewer generic manufacturers for the ER formulation compared to IR, reducing supply redundancy
• International API disruptions: Canada experienced significant lamotrigine supply disruptions in 2024–2025; Australia's TGA listed multiple lamotrigine formulations as in shortage extending into 2026
• Wholesaler heterogeneity: Chain and independent pharmacies use different wholesale networks — a stock-out at one does not mean a stock-out at all

Why Lamictal XR Supply Problems Have High Stakes

Lamotrigine is among the highest-stakes medications for supply continuity:

• Epilepsy: Abrupt discontinuation can precipitate seizures, including status epilepticus. The risk is heightened because XR provides once-daily dosing — patients rely on that single daily dose for 24-hour coverage.
• Bipolar I maintenance: Loss of lamotrigine continuity can trigger severe depressive or mixed episodes, increasing hospitalization risk.
• Titration requirement: If a patient's lamotrigine is discontinued for more than 5 half-lives (~5–10 days depending on concomitant medications), they must restart from the initial titration schedule to minimize rash risk — a 5-week delay in reaching therapeutic doses.

Prescribing Strategies to Protect Patients

These strategies can reduce the risk of supply gaps affecting your patients:

1. Specify Formulation Clearly on Prescriptions

The FDA and manufacturer emphasize: write and say "LAMICTAL XR" clearly to prevent medication errors between IR, XR, and ODT formulations. Write "lamotrigine extended-release" (not just "lamotrigine") on prescriptions to prevent inadvertent substitution by the pharmacist.

38,781+ patients found their medications in stock

38K+

Find Lamictal XR In Stock Today →

2. Consider Whether XR Is Clinically Necessary or Strongly Preferred

For patients where adherence benefit of once-daily XR is critical (e.g., adolescents, patients with complex regimens), the formulation choice is clinically meaningful. For patients who are adherent and stable on IR, the conversion from XR to IR at equivalent total daily dose is pharmacologically reasonable. If you are initiating lamotrigine in a new patient and XR availability in your region is problematic, initiating on IR may avoid future supply complications.

3. Document XR-to-IR Conversion When Clinically Performed

Conversion from XR to IR at equivalent total daily dose is pharmacologically reasonable and widely accepted. Document the reason (supply issue), the equivalence calculation, and that the patient was counseled on the dosing schedule change (once daily → twice daily). Close monitoring for seizure control or mood stability during the transition period is appropriate, especially in well-controlled epilepsy patients.

Skip the calls, skip the stress.

Find Lamictal XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

4. Caution Regarding Manufacturer Switches in Stable Epilepsy Patients

While all generic lamotrigine ER products are AB-rated (FDA-rated as therapeutically equivalent), the American Epilepsy Society and Epilepsy Foundation have historically advised caution when switching AED manufacturers in well-controlled patients. If a patient reports changes in seizure threshold or new symptoms following a manufacturer switch, document their preferred NDC number and work with the pharmacist to maintain manufacturer consistency.

5. Counsel Patients on Restart Titration Requirements

Ensure patients understand that if they have been off lamotrigine for more than 5 half-lives (approximately 5 days when on enzyme inducers; up to 15 days when on valproate), they cannot simply restart at their previous dose. Resumption requires restarting at the initial titration doses to minimize serious rash risk (Stevens-Johnson syndrome). This restart protocol is often unknown to patients and can lead to dangerous self-dosing decisions if the patient manages to find their medication after a gap.

Key Drug Interactions Relevant to Supply-Gap Scenarios

When managing supply gaps, keep these interactions top of mind:

• Valproate: Doubles lamotrigine levels. Patients on valproate + lamotrigine are on lower doses — if transitioning to a non-valproate regimen during a supply gap, dose adjustment is critical.
• Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital, primidone): Decrease lamotrigine levels by ~40%. Patients on these combinations require higher lamotrigine doses.
• Estrogen-containing oral contraceptives: Can decrease lamotrigine levels by ~50%. Levels spike during the pill-free week, potentially causing toxicity symptoms (dizziness, diplopia, ataxia).

Resources for Your Patients and Care Team

Providers can direct patients to medfinder for providers — a service that contacts pharmacies on behalf of patients to locate their specific medication and dosage strength. This reduces the burden on patients who may be medically vulnerable and unable to spend hours on the phone.

See also: How to Help Your Patients Find Lamictal XR in Stock: A Provider's Guide